319.01MMarket Cap-11860P/E (TTM)
5.219High4.940Low319.59KVolume5.190Open5.130Pre Close1.63MTurnover0.84%Turnover RatioLossP/E (Static)62.55MShares5.21952wk High6.23P/B193.79MFloat Cap1.05052wk Low--Dividend TTM38.00MShs Float22.137Historical High--Div YieldTTM5.43%Amplitude0.607Historical Low5.115Avg Price1Lot Size
Corvus Pharmaceuticals Stock Forum
Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
PR Newswire· 9 mins ago
Q2 2024 Represents Second Most Global Ransomware Attacks Reported by Corvus in a Quarter, Average Ransom Demand Increases by 102%
Number 2! Could be that some have stayed on the sidelines waiting to see what the earnings look like! Which is coming o...
No comment yet